BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
151 hedge funds and large institutions have $228M invested in bluebird bio in 2022 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 54 increasing their positions, 41 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
151
Holders Change
-23
Holders Change %
-13.22%
% of All Funds
2.55%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
26
Increased
54
Reduced
41
Closed
45
Calls
$1.84M
Puts
$4.53M
Net Calls
-$2.69M
Net Calls Change
-$1.56M
Top Buyers
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
$24.5M |
| 2 |
Renaissance Technologies
New York
|
$11.6M |
| 3 |
Millennium Management
New York
|
$10.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
$4.13M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
$3.38M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
$7.56M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
$14.5M |
| 3 |
Morgan Stanley
New York
|
$2.69M |
| 4 |
UBS Group
Zurich,
Switzerland
|
$12K |
| 5 |
Rafferty Asset Management
New York
|
$1.09M |
